Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomised, Double-blinded, Placebo Controlled, Crossover Trial to Assess Pantoprazole's Effectiveness as Prophylaxis Against Delayed CINV in Patients Receiving Adjuvant or Neoadjuvant Breast Cancer Chemotherapy

NCT03948477 is registered in ClinicalTrials.gov with University of Auckland, New Zealand as lead sponsor.

NCT NCT03948477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03948477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomised, Double-blinded, Placebo Controlled, Crossover Trial to Assess Pantoprazole's Effectiveness as Prophylaxis Against Delayed CINV in Patients Receiving Adjuvant or Neoadjuvant Breast Cancer Chemotherapy
Lead sponsor
University of Auckland, New Zealand
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2019
Completion date
October 15, 2021
Enrollment
160 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chemotherapy-induced nausea and vomiting, oncology